In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
NEW CVD statistics

The ESC Atlas of Cardiology provides a vast array of CVD data across the ESC's 56 member countries. See how your country compares for CVD risk factors, disease prevelance, cardiology resources and much more.


How does your country compare?

Shaping Policy and Regulation

The ESC's scientific resources and findings from international collaborative projects translate into powerful advocacy messages to drive change at policy and regulatory levels. At the same time, partnering with like-minded stakeholders allows us to be stronger, speaking with one voice, when advocating for change, and to acquire varied perspectives and tools essential to achieve the ESC mission.

ESC Advocacy Committee core action areas are listed below.


COVID-19: The next pandemic wave - CVD

The ESC has warned policy makers that an onslaught of unnecessary cardiovascular deaths could be the next pandemic wave. A significant drop in cardiovascular admissions, coupled with complications linked directly to COVID-19, means a sharp rise in preventable cardiovascular deaths may be on the horizon. Read the statement.


Research, innovation and digital health

Improving opportunities for the pursuit of cardiovascular research in Europe through the identification and promotion of unmet research needs and priorities, securing the necessary funding, and fostering innovative health resources including digital transformation in health.

EU-funded research

The ESC is partner to several EU-funded projects and has taken an active role in public consultations affecting research funding. For example concerning the latter, the ESC responded to a recent public consultation with a call to CV-centred research. The consultation was in response to Professor Mazzucato's vision for a future mission-orientated research approach for EU-funding for projects. More on the ESC's research push at the EU-level.

Clinial trials

Well-conducted randomised clinical trials are the bedrock of safe and effective, evidence-based treatment of cardiovascular disease. However, the cost and complexity of clinical trials has risen out of all proportion. The ESC alongside other leading research organisations, is fighting to improve complex and ineffective clinical trial regulation. Read more

Cancer and cardiology comorbidities

As the European Commission prepares the EU Beating Cancer Plan, the ESC is calling on policymakers to pay greater attention to cancer patients’ long-term well-being and quality of life, addressing the often debilitating comorbidities and complications of cancer. Read more

Digital health

The ESC has representatives working with the European Commission's expert group on Digital Health, the eHealth Stakeholder Group, to ensure the interests of cardiovascular healthcare professionals and their patients.

As a member of the eHealth Stakeholder group, the ESC contributed to the drafting of three policy reports recently, covering the following topics:

More on Digital Health policy and regulation.

Prevention and Public Health

Stimulating evidence-based policy interventions that will shape an environment where healthy lifestyles will be accessible, affordable and appealing.

ESC is an active member of the European Chronic Diseases Alliance (ECDA), founded in 2010 to reverse the alarming rise in chronic diseases by providing leadership and policy recommendations based on contemporary evidence.

The European Heart Health Charter was developed by the ESC and the European Heart Network (EHN), in collaboration with the European Commission and WHO Regional Office for Europe, to prevent cardiovascular disease in Europe.

Health Technologies and Medical Devices

Contributing to the establishment of a regulatory framework promoting innovative, safe and effective health technologies in the area of medical devices and pharmaceuticals.

Since 2010, the ESC has been actively following the medical devices legislative process at EU level. Today, ESC experts take part in European Commission working groups preparing the implementation of the new EU regulatory framework, and have engaged in several advisory processes with EU regulators, as well as with international bodies dealing with global regulatory convergence in the field of medical devices. Find out more.

The ESC is also a member of the European Medicines Agency (EMA) Healthcare Professionals’ Working Party (HCPWP), which provides a platform for exchange of information and discussion of issues of common interest between the Agency and healthcare professionals. 

Open Letter to the Health Commissioner

On the occasion of the World Heart Day (29 September), the ESC and the EHN sent an open letter to the Commissioner-designate for health, Stella Kyriakides.

Read the joint letter

Share your experience

If you are interested in getting involved with the ESC's advocacy activities, please contact us indicating the category EU Affairs.